Bladder cancer radiation
therapy for dogs
in Florida.

When surgery cannot cure it,
multimodal therapy extends life.

Transitional cell carcinoma arises almost always at the trigone of the bladder — the region where the ureters and urethra converge. Complete surgical resection at this location is essentially impossible without removing the entire bladder, which is rarely feasible. The goal of treatment shifts accordingly: maximize tumor control, relieve urinary symptoms, and extend quality of life for as long as possible.

The most common signs — blood in the urine (hematuria), frequent urination, straining to urinate, and recurrent urinary tract infections that don't respond to antibiotics — should prompt imaging evaluation. Ultrasound typically identifies a bladder mass; CT provides full staging including lymph node involvement and distant metastasis.

The role of radiation in bladder TCC

Palliative radiation therapy for bladder TCC reduces local tumor volume, relieves urinary obstruction, decreases hematuria, and can prevent ureteral obstruction that would otherwise cause kidney failure. Radiation is typically combined with piroxicam or meloxicam (NSAIDs, which have documented anti-tumor activity against TCC) and sometimes with vinblastine or mitoxantrone chemotherapy.

Precision planning for a challenging location

Radiation to the bladder trigone must spare adjacent structures — rectum, urethra, small intestine — while delivering therapeutic doses to the tumor. This requires precise CT simulation, conformal treatment planning, and careful dose-volume constraint management. At AARADONC, every bladder TCC plan is designed with adjacent organ protection as a primary objective.